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Abstract
Purpose—To compare the five year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) and 
the Baerveldt 101-350 Glaucoma Implant (BGI) for the treatment of refractory glaucoma.
Design—Multicenter randomized controlled clinical trial.
Participants—276 patients, including 143 in the AGV group and 133 in the BGI group.
Methods—Patients 18 to 85 years of age with previous intraocular surgery or refractory 
glaucoma and intraocular pressure (IOP) of ≥ 18 mmHg in whom glaucoma drainage implant 
surgery was planned were randomized to implantation of either an AGV or BGI.
Main Outcome Measures—IOP, visual acuity, use of glaucoma medications, complications, 
and failure (IOP > 21 mmHg or not reduced by 20% from baseline, IOP ≤ 5 mmHg, reoperation 
for glaucoma, removal of implant, or loss of light perception).
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Results—At 5 years, IOP (mean ± SD) was 14.7 ± 4.4 mmHg in the AGV group and 12.7 ± 4.5 
mmHg in the BGI group (p = 0.012). The number of glaucoma medications in use at 5 years 
(mean ± SD) was 2.2 ± 1.4 in the AGV group and 1.8 ± 1.5 in the BGI group (p = 0.28). The 
cumulative probability of failure during 5 years of follow-up was 44.7% in the AGV group and 
39.4% in the BGI group (p = 0.65). The number of subjects failing due to inadequately controlled 
IOP or reoperation for glaucoma was 46 in the AGV group (80% of AGV failures) and 25 in the 
BGI group (53% of BGI failures, p=0.003). Eleven AGV eyes (20% of AGV failures) experienced 
persistent hypotony, explantation of implant, or loss of light perception compared to 22 (47% of 
failures) in the BGI group. The 5-year cumulative reoperation rate for glaucoma was 20.8% in the 
AGV group compared to 8.6% in the BGI group (p=0.010). Change in logMAR Snellen visual 
acuity (mean ± SD) at 5 years was 0.42 ± 0.99 in the AGV group and 0.43 ± 0.84 in the BGI 
group (p=0.97).
Conclusions—Similar rates of surgical success were observed with both implants at 5 years. 
BGI implantation produced greater IOP reduction and a lower rate of glaucoma reoperation than 
AGV implantation but BGI implantation was associated with twice as many failures due to safety 
issues such as persistent hypotony, loss of light perception, or explantation.
Glaucoma drainage implants (GDI) have been used with increasing frequency in the 
management of glaucoma refractory to trabeculectomy, even in the era of antifibrotic agent 
use. Medicare data reveals a marked increase in the use of GDIs, from just over 2,000 in 
1994 to almost 12,000 in 2012 (William Rich, III, personal communication). In addition, 
surveys of the membership of the American Glaucoma Society performed in 1996, 2002, 
and 2008 show a significant increase in the use of GDIs in patients who had undergone prior 
surgery or who had neovascular or uveitic glaucoma compared to trabeculectomy with 
mitomycin-C.1–3 This shift in practice pattern has been validated by the results of the Tube 
Versus Trabeculetomy (TVT) Study,4 which found that patients with prior trabeculectomy 
and/or prior cataract surgery had a higher success rate with GDI surgery compared with 
trabeculectomy with mitomycin-C.
GDIs share a common design consisting of a tube that is inserted into the eye through a 
scleral fistula and shunts aqueous humor to an end plate placed in the equatorial region. 
They differ with respect to the size and material composition of the end plate, as well as the 
presence or absence of a valve that restricts aqueous flow if the intraocular pressure (IOP) 
becomes too low. A limited number of studies exist comparing different implant designs, 
and most of these are retrospective case series.5 A recent Ophthalmic Technology 
Assessment of GDIs performed by the American Academy of Ophthalmology’s Technology 
Assessment Committee concluded that “Too few high-quality direct comparisons of various 
available shunts have been published to assess the relative efficacy or complication rates of 
specific devices….”6 The Ahmed Baerveldt Comparison (ABC) and Ahmed Versus 
Baerveldt (AVB) Studies were initiated to compare the safety and efficacy of the Ahmed 
Glaucoma Valve (AGV FP7, New World Medical, Cucamonga, CA) and the Baerveldt 
Glaucoma Implant (BG 101-350, Abbott Medical Optics, Abbott Park, IL), the two most 
commonly used GDIs in the United States. These randomized prospective clinical trials have 
shown similar results through 3 years of follow-up.7,8 Specifically, both studies showed a 
small difference in IOP (1.2 – 1.3 mmHg lower in the BGI group) on slightly fewer 
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medications (0.5 – 0.7 in the BGI group) with more subjects failing due to elevated IOP in 
the AGV group. The purpose of the current study is to report the 5-year treatment outcomes 
in the ABC Study.
METHODS
The Institutional Review Board at each of 16 Clinical Centers approved the study protocol 
before recruitment was started, and each patient gave informed consent. The study was 
registered at www.clinicaltrials.gov (accessed February 16, 2014). The design and methods 
of the ABC Study are described in detail in a baseline methodology paper,9 and are 
summarized as follows.
Randomization and Treatment
Patients age 18–85 years with refractory glaucoma and IOPs ≥to 18 mmHg in whom GDI 
surgery was planned were enrolled in the study. Patients with primary glaucomas with a 
previous failed trabeculectomy or other intraocular surgery were included. Also, patients 
without previous intraocular surgery were eligible if they had secondary glaucomas known 
to have a higher risk of trabeculectomy failure such as neovascular glaucoma (NVG), uveitic 
glaucoma, or glaucoma associated with iridocorneal endothelial (ICE) syndrome. Exclusion 
criteria included no light perception at baseline, uveitic glaucoma secondary to Juvenile 
Rheumatoid Arthritis, prior glaucoma drainage implant or cyclodestructive procedure, need 
for concurrent or anticipated (within 6 months) non-glaucoma surgery (cataract, corneal, 
vitreoretinal, superotemporal scleral buckle or retinal sponge precluding superotemporal 
placement of an implant, or inability to provide informed consent.
Eligibility was independently confirmed at the Statistical Coordinating Center (SCC) at the 
Bascom Palmer Eye Institute. Individuals enrolled in the study were randomized to 
placement of an AGV FP7 or BG 101-350 according to a permuted variable block 
randomization scheme, stratified by surgeon within Clinical Center and type of glaucoma. 
Patients were allocated to one of 4 strata according to their type of glaucoma, as follows: (1) 
Primary glaucomas with previous intraocular surgery; (2) Secondary glaucomas (excluding 
uveitic glaucoma and NVG); (3) NVG; and (4) Uveitic glaucoma. Neither the subject nor 
investigator was masked to the randomization assignment. Only one eye of each patient was 
eligible for enrollment. Details of the inclusion and exclusion criteria, recruitment method, 
and surgical procedures for AGV and BGI implantation used in this study are described in 
the baseline paper.9
Patient Visits
Follow-up visits were scheduled one day, one week, one month, three months, six months, 
one year, 18 months, two years, three years, four years, and five years postoperatively. 
Information about data obtained at baseline and follow-up visits is contained in the baseline 
paper.9
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Primary and Secondary Outcome Measures
The primary outcome measure was failure, based on consensus definitions contained in the 
World Glaucoma Association Guidelines on Design and Reporting of Surgical Trials.11 
These criteria for failure were defined prospectively as IOP > 21mmHg or less than a 20% 
reduction below baseline on 2 consecutive study visits after three months, IOP ≤ 5 mmHg 
on 2 consecutive study visits after three months, reoperation for glaucoma, loss of light 
perception, or removal of the implant for any reason. Reoperation for glaucoma was defined 
as additional glaucoma surgery requiring a return to the operating room. Cyclodestruction 
was counted as a reoperation for glaucoma, irrespective of whether or not the procedure was 
performed in the operating room. Interventions performed at the slit lamp, such as needling 
procedures, removal of occluding stents, or laser suture lysis, were not considered glaucoma 
reoperations. IOP, use of glaucoma medications, visual acuity, visual fields, and rates of 
surgical complications were secondary outcome measures in the ABC Study. Eyes that had 
not failed by the above criteria and were not on glaucoma medical therapy were considered 
complete successes, and those requiring adjunctive medical therapy were defined as 
qualified successes.
Statistical Analysis
Snellen VA measurements were converted to logarithm of the minimum angle of resolution 
visual acuity (logMAR VA) equivalents for the purpose of data analysis, as reported 
previously.12 The time to failure was defined as the time from GDI placement to either 
reoperation for glaucoma, loss of acuity to no light perception (NLP) in the study eye, or the 
first of two consecutive follow- up visits after three months in which the patient had 
persistent hypotony (IOP ≤ 5 mmHg) or inadequately controlled IOP (IOP > 21 mmHg or 
not reduced by 20%). Data on IOP and numbers of glaucoma medications were censored 
once a patient underwent a reoperation for glaucoma, explantation of the implant, or loss of 
light perception, but not after failure due to high IOP, hypotony, or reoperation for a 
complication. There was no censoring of visual acuity results. Univariate comparisons 
between treatment groups were performed with the two-sided Student t-test for continuous 
variables and the chi-square test or Fisher’s exact test for categorical variables. Risk factors 
for treatment failure were assessed for statistical significance with the Kaplan-Meier 
survival analysis log-rank test. Multivariate analysis was performed with Cox proportional 
hazard regression analysis with forward stepwise elimination. Patients’ data were analyzed 
in the group to which they were assigned during randomization (intent-to-treat analysis). A 
p–value of 0.05 or less was considered statistically significant in our analyses.
RESULTS
Recruitment and Retention
A total of 276 patients were enrolled between October 2006 and April 2008, including 143 
patients (52%) who were randomized to placement of an AGV and 133 patients (48%) to a 
BGI. Protocol violations are described in the baseline paper.9
Retention of patients in the study through 5 years of follow-up is shown in Figure 1. In the 
overall study group, 174 (63%) patients completed their 5-year visit. This included 87 (61%) 
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patients in the AGV group and 87 (65%) in the BGI group. We compared the numbers of 
patients who did not complete a five year visit (n=81) by treatment group, excluding from 
analysis those who had died prior to the end of the 5 year visit window (n=21). No 
significant difference was observed in the proportion of patients who did not complete 5-
year visits in the AGV group, 44 (34%), and the BGI group, 37 (30%) (p = 0.59, Fisher 
exact test). There was no difference between randomized treatment groups in either mean 
IOP or mean numbers of IOP lowering medicines between those followed until the next 
annual visit and those lost to follow up (all p > 0.2, two way analysis of variance with test of 
interaction between treatment group and loss to follow up during the next year).
Baseline Characteristics
There were no differences in baseline demographic or clinical characteristics between the 
two groups, as detailed in the baseline paper.9
IOP Reduction
The baseline and follow-up IOPs for the two groups are reported in Table 1 and Figure 2. 
Patients who underwent additional glaucoma surgery, removal of the implant, or loss of light 
perception were censored from analysis after these events. Both study groups experienced a 
significant reduction in IOP postoperatively. Among patients with 5 year follow-up in the 
AGV group, IOP (mean ± standard deviation; SD) was reduced from 29.6 ± 10.1 mmHg at 
baseline to 14.7 ± 4.4 mmHg at the five-year follow-up visit (p < 0.001, paired t-test). In the 
BGI group, IOP (mean ± SD) was reduced from 28.3 ± 9.3 mmHg at baseline to 12.7 ± 4.5 
mmHg at the five-year follow-up visit (p < 0.001, paired t-test). The IOP difference between 
the two treatment arms at five years was statistically significant (p=0.015) using analysis of 
covariance, which takes into account preoperative IOP differences. The AGV group had a 
significantly lower mean IOP than the BGI group at the one day and one week follow-up 
visits. However, the mean IOP in the BGI group was approximately 1 to 2 mmHg lower 
than the AGV group thereafter, except at the two-year visit. The 1.3mmHg difference in 
baseline IOP between AGV and BGI patients who returned for 5 year follow up was not 
statistically significant (p=0.37). Furthermore, accounting for preoperative IOP with analysis 
of covariance did not alter the statistical significance of any of the comparisons of post-
operative IOPs between the AGV and BGI groups. Mean IOP in the AGV and BGI groups 
did not vary significantly between the four study strata at any of the annual follow up visits 
(all p > 0.2, two way analysis of variance with test of interaction).
Medical Therapy
Table 1 also shows the number of glaucoma medications in both groups at baseline and 
follow-up. Patients who underwent surgery glaucoma reoperation, removal of the implant, 
or loss of light perception were censored from analysis. There was a significant reduction in 
the need for medical therapy in both treatment groups (Figure 3). The number of glaucoma 
medications (mean ± SD) in the AGV group decreased from 3.5 ± 1.0 at baseline to 2.2 ± 
1.4 at the five-year follow-up visit (p < 0.001, paired t-test). The number of glaucoma 
medications (mean ± SD) in the BGI group was reduced from 3.5 ± 1.1 at baseline to 1.8 ± 
1.5 at the five-year follow-up visit (p < 0.001, paired t-test). Patients in the AGV group were 
using significantly more medications at years two through four as compared to the BGI 
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group. There was no statistical difference between treatment groups with regard to the 
number of medications in use at 5 years or the reduction in medications from baseline to 5 
years. Mean number of medications in the AGV and BGI groups did not vary significantly 
between the four study strata at any of the annual follow up visits (all p > 0.2, two way 
analysis of variance with test of interaction).
Treatment Outcomes
Table 2 compares the outcomes and reasons for failure of randomized patients, unadjusted 
for follow-up time. All patients who were seen at the five-year follow-up visit and/or failed 
during the first five years of the study were included in this analysis. While the total 
numbers of failures were similar in the two groups, the reasons for treatment failure were 
different between the AGV and BGI groups (p=0.012, exact chi-square test). The number 
failing due to inadequately controlled IOP or reoperation for glaucoma was 46 in the AGV 
group (representing 80% of AGV failures) compared to 25 in the BGI group (53% of BGI 
failures), a statistically significant difference (p=0.003). Only 11 AGV eyes (20% of AGV 
failures) experienced persistent hypotony, complications for which explantation was 
performed, or loss of light perception in the study eye compared to 22 (47% of failures) in 
the BGI group.
Kaplan-Meier survival analysis was used to compare failure rates between the two treatment 
groups (Figure 4). The cumulative probability of failure (standard error, SE) was 44.7% 
(4.6%) in the AGV group and 39.4% (4.6%) in the BGI group at five years (p=0.65, log-
rank test). The relative risk of treatment failure in the AGV group was 1.1 times that in the 
BGI group (95% Confidence Interval (CI): 0.8–1.7, p=0.52 Cox proportional hazards 
regression). There was no suggestion of different treatment effects in the four randomized 
strata (p = 0.52, three degree of freedom test of treatment group by stratum interaction). To 
investigate the timing of failures over follow-up, we calculated annual hazard rates during 
each of the five study years. The hazard rate (SE) of failure was highest in the first two years 
of follow-up, 1.5% (0.02%) and 1.3% (0.2%), respectively, and decreased in years three and 
four, 0.5% (0.2%) and 0.4% (0.8%), with a modest increase in the last year of the study, 
0.8% (0.2%). There was no difference in the pattern of hazard rates over time between the 
study strata.
The cumulative proportion of patients undergoing reoperation for glaucoma during 5 years 
of follow-up was 20.8% in the AGV group compared to 8.6% in the BGI group (p = 0.010, 
log-rank test; Figure 5). The relative risk of reoperation for glaucoma in the AGV group was 
2.6 times that of the BGI group (95% CI:1.2–5.3, p = 0.012; Cox proportional hazards 
regression). Table 3 presents the specific reoperations for glaucoma performed in the two 
treatment groups.
The failure rates for the AGV and BGI treatment groups were examined using alternative 
outcome criteria. Patients with persistent hypotony, reoperation for glaucoma, or loss of 
light perception were still classified as treatment failures; however, the upper IOP limit 
defining success and failure was changed. When inadequate IOP control (with or without 
medications) was defined as IOP greater than 17 mmHg or not reduced by 20% on two 
consecutive follow-up visits after three months, the cumulative probability of failure at five 
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years (SE) was 60.4% (4.5%) in the AGV group and 46.1% (4.7%) in the BGI group (p = 
0.048, stratified log rank test). When inadequate IOP control was defined as IOP greater 
than 14 mmHg or not reduced by 20% on two consecutive follow-up visits after three 
months, the cumulative probability of failure was 77.6% (3.9%) in the AGV group and 
64.4% (4.5%) in the BGI group at five years (p = 0.003, stratified log rank test).
Patients with a five-year follow up visit who were still successful through that visit were 
divided into complete and qualified success based on the requirement for IOP-lowering 
medical therapy at five years. The number (%) of complete successes at five years was 9 
(8%) in the AGV group compared to 14 (14%) in the BGI group (Table 4, p = 0.27). Table 4 
also reviews in detail the percent of treatment failures, complete, and qualified success in the 
two arms of the study by stratum. The study was not adequately powered to reach 
conclusions about the differences between treatment arms in these subgroups. That being 
said, there does not appear to be much difference in outcomes within the diagnostic strata.
Because the surgeon was not masked to the treatment assignment, a potential bias existed in 
the decision to reoperate for IOP control. To evaluate for reoperation bias, the IOP levels 
were compared between treatment groups among patients who failed because of inadequate 
IOP control. For cases failing by high IOP at two consecutive study visits without 
reoperation, the average of the failing IOPs was calculated and compared between the two 
treatment groups. The failing IOP (mean ± SD) in the AGV group was 20.0 ± 4.4 mmHg 
compared to 23.0 ± 6.4 mm Hg in the BGI group (p=0.089, two-sample t237 test). The IOP 
immediately prior to glaucoma reoperation was also compared between treatment groups. 
Among AGV cases reoperated for glaucoma, the preoperative IOP (mean ± SD) 
immediately prior to reoperation was 28.9 ± 9.0 mm Hg compared to 29.4 ± 6.3 mm Hg in 
the BGI group (p=0.90).
Visual Acuity
Visual acuity results are shown in Table 5. There was a significant decrease in Snellen VA 
in both treatment groups during the five years of follow-up. In the AGV group, logMAR 
Snellen VA (mean ± SD) decreased from 1.07 ± 1.01 at baseline to 1.42 ± 1.15 at the five-
year follow-up visit (p <0.001, paired t-test). In the BGI group, logMAR Snellen VA (mean 
± SD) decreased from 1.04 ± 1.00 at baseline to 1.43 ± 1.40 at the five-year follow-up visit 
(p < .001, paired t-test). There was no significant difference in logMAR Snellen VA 
between the two groups at five years (p = 0.97, student t-test).
Snellen VA was decreased by two or more lines from baseline in 36 (42%) patients in the 
AGV group and 38 (44%) patients in the BGI group at five years, and this difference was 
not significantly different (table 5, p = 0.88, Fisher’s exact test). The most frequent causes of 
vision loss during five years of follow-up were glaucoma, retinal disease, and anterior 
segment pathology. The reason for decreased vision was unknown in 5 (14%) patients in the 
AGV group and 2 (5%) patients in the BGI group. The other miscellaneous cause for 
reduced vision in the AGV group was due to a patient with Alzheimer’s who did not 
perform the acuity test well. Other causes of vision loss in 5 patients in the BGI group 
included phthisis bulbi and posterior capsular opacification. There were no significant 
differences in the reasons for visual acuity loss between the two treatment groups. Of 161 
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patients with visual acuities measured at both the three and five year visits, 32 patients 
(20%) lost 2 or more Snellen lines of acuity between their 3 and 5 year visits. Reasons for 
acuity loss were glaucoma alone or in combination with another cause in 14 patients (44%), 
retinal disease in the absence of glaucoma in 7 patients (22%), corneal disease in 5 patients 
(16%), cataract alone in 1 patient (3%), and in 4 patients (13%) the reason was not recorded.
Twenty-five patients (9%) progressed to NLP vision, 6 of which had previously failed by 
one of the other criteria, and all but one of these (96%) of these were in the neovascular 
glaucoma (NVG) stratum. We compared the incidence of NLP between randomized 
treatment groups among the 80 NVG patients. At 5 years, the cumulative proportion of 
NVG patients who progressed to NLP in the AGV group was 28.3% (SE=8.9%) compared 
to 51.1% (SE=9.2%) in the BGI group, a difference which was statistically significant 
(p=0.030, log-rank test). In the judgment of the surgeons, neovascular eyes which lost light 
perception in the Ahmed group did so for the following reasons: glaucoma (4), progressive 
diabetic retinopathy (3), no reason provided (1). In the Baerveldt group reasons included: 
macular disease (2), phthisis bulbi (3, 1 following retinal detachment), vitreous hemorrhage/
hyphema (1), glaucoma (2), enucleation of painful eye (1), unable to determine due to 
anterior segment pathology (1), progressive diabetic retinopathy (1), ischemia (1), no reason 
provided (4).
DISCUSSION
The ABC Study is a multicenter prospective clinical trial comparing the two most popular 
GDIs. Patients with previous intraocular surgery or refractory glaucoma were enrolled in the 
study and randomly assigned to surgical treatment with the Ahmed FP7 and Baerveldt BG 
101-350. Baerveldt implantation was more effective in providing long-term IOP control than 
Ahmed implantation. The BGI produced greater IOP reduction with fewer adjunctive 
medications and required fewer glaucoma reoperations compared with the AGV during 5 
years of follow-up.
We recognize that the goal of glaucoma therapy is the prevention of further glaucomatous 
optic nerve damage and visual field loss with preservation of visual function. The degree of 
IOP reduction is a surrogate for successful glaucoma therapy, primarily because IOP is 
easily measurable and the only known treatable risk factor for glaucoma progression. As 
such, it serves as an important measure of surgical success. Both the AGV and BGI 
produced profound reductions in IOP, from baseline averages of 31 – 32 mmHg to final 
average IOPs of 14.7 mmHg in the AGV group and 12.7 mmHg in the BGI group. The total 
IOP reduction was greater than 50% in both treatment groups, which is comparable to 
previous studies of GDIs.5 The BGI group had a mean IOP approximately 2 mmHg lower 
IOP than the AGV group at most of the annual study visits, including at 5 years, and this 
represents a statistically significant difference. The lower IOPs in the BGI group were 
achieved with fewer glaucoma medications compared with the AGV group at most time 
intervals.
There are two reasons that may be offered to explain the superior IOP control observed with 
the BGI relative to the AGV. First, studies have shown that glaucoma drainage devices with 
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larger end plates result in lower IOPs.5 Heuer and colleagues13 found higher success rates 
and lower long-term IOPs using the double-plate compared to the single-plate Molteno 
implant. However, there may be an upper limit of benefit of end plate size, as Britt et al14 
subsequently noted similar outcomes when comparing the Baerveldt 500 mm2 implant to the 
350 mm2 in a prospective clinical trial. A recent retrospective study by Seah et al15 
comparing the Baerveldt 250 mm2 versus 350 mm2 implant found no difference in final IOP 
between the two implant sizes. A prospective randomized trial comparing these two end 
plate sizes is underway (clinicaltrials.gov, registered July 8, 2010). The second possible 
explanation for lower long300 term IOPs with the BGI relates to exposure of the filtering 
bleb to postoperative inflammatory material. In the valved AGV, there is immediate flow of 
aqueous to the bleb, exposing it to inflammatory cells, cytokines, and proteins resulting from 
the surgery, which may produce more vigorous scarring of the fibrous capsule surrounding 
the end plate.5,16 In the non-valved BGI, complete occlusion of the tube for the first four to 
six weeks is critical to prevent early hypotony and hypotony-related complications such as 
flat anterior chambers, choroidal effusions, and suprachoroidal hemorrhages.17 By occluding 
the BGI for a period of several weeks, the bleb is exposed to much less inflammatory 
material. Whatever the explanation, the larger, non-valved BGI tends to produce better long-
term IOP control, which may make it the preferred implant in patients in whom one is trying 
to achieve the lowest possible IOP postoperatively.
The primary outcome in the ABC Study was cumulative failure rate at 5 years. 
Approximately 40% of subjects in both groups failed by criteria defined a priori, based on 
failure criteria recommended by a consensus group of the World Glaucoma Association.11 It 
is interesting to note that the two treatment groups failed at approximately the same rate, but 
they did so for different reasons. The AGV group failed due to high IOP endpoints, while 
the BGI group failed due to safety endpoints. Higher IOPs in the AGV group resulting in 
failure or reoperation for glaucoma may be related to the smaller end plate or immediate 
release of inflammatory factors to the sub-Tenon’s space, as discussed above. The higher 
rate of hypotony in the BGI group is likely related to the larger size of the end plate and the 
lack of a flow restrictor, the same design features that resulted in fewer failures due to lack 
of IOP control. A higher rate of surgical success was seen with the BGI compared with the 
AGV in post hoc analyses when IOP failure was stringently defined as IOP greater than 14 
mm Hg.
Only 8% of subjects who underwent AGV implantation and 14% of those undergoing BGI 
implantation had controlled IOP without medications at 5 years (complete success). In the 
TVT study, the tube (BGI) group had a complete success rate of 25% but the subjects in the 
TVT study were at lower risk of surgical failure than the current study since the TVT study 
excluded patients with secondary glaucomas such as ICE syndrome, uveitis, and neovascular 
glaucoma. Table 4 shows the complete success rate by stratum in the ABC study at 5 years. 
In stratum 1, which is identical to the subjects addressed by the TVT study, the complete 
success rate is 21%, very similar to the 25% complete success rate in the TVT BGI group.
The rate of reoperation for glaucoma was higher in the AGV group relative to the BGI 
group. Patients who required additional glaucoma surgery underwent placement of a second 
GDI or cyclodestruction in both treatment groups. Because investigators were not masked to 
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the treatment assignment and the decision to reoperate was left to the surgeon’s discretion, a 
potential for bias existed in the decision to reoperate for glaucoma. No significant difference 
in mean IOP at the time of failure was seen between treatment groups in patients who had a 
reoperation for glaucoma, or in patients who failed because of inadequate IOP reduction but 
did not have additional glaucoma surgery. These observations suggest that no selection bias 
was present for glaucoma reoperation.
Visual acuity decreased in both treatment groups during the five years of follow-up. 
Approximately 43% of subjects lost 2 or more lines of Snellen visual acuity. Snellen acuity 
was the same in the treatment groups at year 5 and no significant differences in the rates and 
reasons for vision loss were present in the AGV and BGI groups. Many of the causes of 
vision loss, such as progression of diabetic retinopathy or age related macular degeneration, 
were not directly attributable to the surgical procedures under study. Compared to the 3 year 
study results,7 there were no additional subjects who lost 2 or more lines of vision but there 
were eight additional subjects in the BGI group who lost 2 or more lines of vision. The 
proportion of subjects who lost 2 or more lines of vision in the current study and the 
magnitude of vision lost between the preoperative and 5 year visit was very similar to that 
seen in the 5-year results of the TVT Study.4
Several retrospective case series have compared the AGV and BGI.18–22 Unfortunately, the 
surgeon’s GDI selection in these studies may have been influenced by the patient’s 
presumed risk of failure and could bias the results. Randomized clinical trials are designed 
to produce comparison groups that differ only by the treatment provided, and they offer the 
highest level of evidence-based medicine. The Ahmed Versus Baerveldt (AVB) Study is 
another multicenter randomized prospective clinical trial comparing the safety and efficacy 
of the AGV and BGI. Both the ABC and AVB Studies observed significantly greater long-
term IOP reduction and less need for glaucoma medical therapy with the BGI compared to 
the AGV with similar success rates after 3 years of follow-up. The similarity in results 
between these clinical trials has allowed each study to validate the other.
There are several limitations to the ABC Study. Neither the patient nor the surgeon was 
masked to the implant used. The study only evaluated the AGV and BGI, and the results 
cannot be extrapolated to other GDIs or different models of the AVG or BGI. Patients were 
excluded if other ocular procedures were required in conjunction with glaucoma surgery, so 
the study does not provide information about the preferred implant when concurrent ocular 
surgery is needed. While aspects of both surgical procedures were standardized, some 
variation in surgical technique occurred between surgeons. We felt that it was important to 
provide latitude for the surgeon to perform the procedures under study in a manner in which 
he/she was proficient. Also, the results apply only to the diagnostic groups included in the 
study. Specifically, these results cannot be generalized to patients without prior incisional 
surgery who are low-risk for failure of standard surgery (such as trabeculectomy).
The ABC Study does not demonstrate clear superiority of one implant over the other. In 
addition to efficacy and safety data, there are other important considerations. The individual 
patient characteristics and surgeon’s comfort and experience with each implant are critical in 
device selection. The benefits of each implant in reducing IOP must be interpreted in light of 
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its surgical complications (manuscript forthcoming). The valve mechanism of the AGV 
allows the implant to function immediately postoperatively, and this may be particularly 
advantageous in patients with markedly elevated IOP preoperatively. For instance, patients 
with neovascular glaucoma with completely closed anterior chamber angles typically have 
markedly elevated IOP that is unresponsive to medical therapy and need immediate IOP 
lowering; one would prefer a valved implant in this instance since one would not want to 
wait the typical 5 – 7 weeks for a suture ligature to dissolve in an non-valved implant such 
as the BGI. In addition, NVG patients typically do not have significant glaucomatous 
cupping at presentation since their IOP has been elevated for a relatively short period of 
time. For these reasons, perhaps one would prefer the smaller-plated valved AGV implant 
and be willing to sacrifice the modestly lower average IOP achievable with the larger, non-
valved BGI implant. The AGV implant may also be preferred in patients at greater risk for 
postoperative hypotony, such as those with uveitic glaucoma or prior cyclodestruction. In 
these patients, decreased aqueous humor production may induce hypotony if there is excess 
outflow in a large non-valved implant such as the BGI. In either group of patients, NVG or 
inflammatory glaucomas, if the IOP is too high in the long-term, a larger, non-valved 
implant can usually be placed in a second quadrant. The above clinical suggestions should 
be backed up, however, with future properly powered randomized clinical trials since the 
current study did not have enough subjects in these subgroups to come to definitive 
conclusions on which implant is best used in which subgroup.
It is interesting to compare the results of the ABC Study at three and five years. From zero 
to three years, the failure rates in the two groups were approximately 10% per year, with a 
cumulative failure rate of 30% in both groups at year three. From three to five years, the 
failure rate seems to flatten such that an additional 10% of subjects failed in the last two 
years of follow up for a rate of 5% failure per year. It seems that, once patients make it 
through the first 3 years there is a lower rate of failure going forward, although longer 
follow-up would be helpful to confirm this. Also, it is interesting to note that the IOP and 
number of medications remained stable between years three to five as the had been in years 
one three. Similar to the five year results of BGI 101-350 in the Tube vs. Trabeculectomy 
Study,4 IOP was, on average, between 13 and 15 mmHg on an average of two medications.
In summary, BGI implantation produced greater IOP reduction and a lower incidence of 
glaucoma reoperation than AGV implantation after 5 years of follow-up. The AGV 
decreased IOP to a greater degree in the early postoperative period compared with the BGI. 
Similar rates of surgical success were observed with both implants during 5 years of follow-
up, but the reasons for treatment failure were different. Failure after AGV was usually due to 
high IOP endpoints, while failure with the BGI was most commonly related to safety 
endpoints (hypotony, implant explantation, and loss of light perception). The approximate 2 
mmHg additional IOP lowering obtained with the BGI must be weighed against the higher 
number of safety endpoints in the BGI group compared to the AGV group. A detailed 
account of the complications following 5 years of follow-up from this study is forthcoming.
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Figure 1. Study Flow Diagram
Recruitment and retention in the ABC Study at five years.
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Figure 2. IOPs by randomized treatment group and follow-up visit
Graph of IOP (mmHg) in the ABC Study by study group from preoperative level through 
five year follow-up visit (mean ± SD).
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Figure 3. Medication use by randomized treatment group and follow-up visit
Histogram of the number of classes of ocular hypotensive medication used from before 
surgery through five year follow-up visit (mean ± SD).
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Figure 4. Kaplan-Meier cumulative surgical failure rates by randomized treatment group
Kaplan-Meier survival curve of cumulative surgical failures through five years of follow-up 
by treatment group.
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Figure 5. Kaplan-Meier cumulative reoperation rates by randomized treatment group
Kaplan-Meier survival curve of cumulative reoperation rates in through five years of follow-
up by treatment group.
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Table 1
Intraocular Pressure and Medical Therapy at Baseline and Follow-up in the Ahmed Baerveldt Comparison 
Study
Ahmed Group Baerveldt Group P-value*
Baseline
  IOP (mm Hg)











  IOP (mm Hg)
  Glaucoma medications










  IOP (mm Hg)
  Glaucoma medications










  IOP (mm Hg)
  Glaucoma medications










  IOP (mm Hg)
  Glaucoma medications










  IOP (mm Hg)
  Glaucoma medications









Data are presented as mean ± standard deviation.
IOP and number of medications are censored after treatment Failure by no light perception, reoperation for glaucoma, or explantation for 
complication.
IOP = intraocular pressure
*
Student t-test
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Table 2
Reasons for Treatment Failure in the Ahmed Baerveldt Comparison Study
Ahmed Group Baerveldt Group
Inadequate IOP control without additional glaucoma surgery# 23 (40%) 17 (36%)
Reoperation to lower IOP 23 (40%) 8 (17%)
Explantation for complication 3 (5%) 4 (8%)
Persistent hypotony* 1 (2%) 6 (13%)
Loss of light perception 7 (12%) 12 (26%)
Total 57 47
Data are presented as number (percentage of the total number of Failures in each respective treatment group). There was a statistically significant 
difference in the distribution of types of Failures between the AGV and BGI implants (p=0.012, exact chi-square test).
IOP = intraocular pressure
#
IOP > 21 mmHg at 2 consecutive visits after 3 months
*
IOP ≤ 5 mm Hg at 2 consecutive visits after 3 months
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Table 3





Additional tube shunt 13 8
Cyclodestructive procedure 12 2
Tube revision followed by cyclodestructive procedure 1 0
Total number of patients (5 year cumulative Kaplan-Meier percentage ± SE) with reoperation for 
glaucoma*
26 (20.8 ± 3.7%) 10 (8.6 ± 2.6%)
Data are presented as number of patients.
*
P = 0.010 for the difference in 5-year cumulative reoperation rates for glaucoma between treatment groups from Kaplan-Meier analysis (log rank 
test adjusted for stratum)
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Table 4
Treatment Outcomes after 5 Years of Follow-up in the Ahmed Versus Baerveldt Comparison Study
Ahmed Group Baerveldt Group
Stratum 1—primary glaucomas with previous intraocular surgery
  Failure
  Qualified success







Stratum 2—secondary glaucomas (excluding neovascular and uveitic glaucomas)
  Failure
  Qualified success









  Qualified success







Stratum 4— uveitic glaucoma
  Failure
  Qualified success









  Qualified success







Data presented as number of patients (percentage).
*
P = 0.27 for the difference in Complete success rates between treatment groups (binomial logistic regression model including both randomized 
treatment group and stratum as independent variables)
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Table 5






Snellen VA, logMAR mean ± SD
  Baseline (n=276)
  5 years (n=174)










Loss of ≥ 2 Snellen lines at 5 years, n (%)*
  Glaucoma
  Retinal disease



















logMAR = Logarithm of the Minimum Angle of Resolution
*
Patients may have more than one reason for decreased vision.
†




Other reasons for vision loss included phthisis bulbi (n=3), posterior capsule opacification (n=2), inability to perform acuity test (Alzheimer’s 
Disease, n=1)
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